Genocea Biosciences Secures $30,000,000 Series C Financing
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=120b514e-6cfe-4e38-a16d-ee2f1c16c51b&Preview=1 -
Date
10/10/2012 -
Company Name
Genocea Biosciences -
Mailing Address
161 First Street Cambridge, MA 02142 -
Company Description
Genocea is developing a new class of human vaccines based on a revolutionary platform for the rapid discovery of antigens that induce T cell immunity. The platform, which dramatically reduces the time to discover vaccine candidates, uniquely employs a proprietary, high-throughput approach that mimics the natural immune response in the laboratory to comprehensively screen for antigens that are protective across diverse human populations. -
Website
http://www.genocea.com -
Transaction Type
Venture Equity -
Transaction Amount
$30,000,000 -
Transaction Round
Series C -
Proceeds Purposes
The developer has been ramping up a Phase I/IIa study of its lead program–GEN-003–for herpes simplex virus-2. -
M&A Terms
-
Venture Investor
Bill & Melinda Gates Foundation -
Venture Investor
Johnson & Johnson Development Corporation -
Venture Investor
Skyline Ventures -
Venture Investor
Polaris Venture Partners -
Venture Investor
SR One -
Venture Investor
Lux Capital -
Venture Investor
Cycad Group -
Venture Investor
Auriga Partners -
Venture Investor
Morningside Group
